A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC

SOCRATES HCC will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use heating probes directly inserted into the tumour or chemotherapy or radioactive particles injected into the blood supply of the tumour.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australasian Gastro-Intestinal Trials Group (AGITG), Abdominal Radiology Group of Australia and New Zealand (ARGANZ) & Gastrointestinal Society of Australia (GESA)

Participating Centres

Accrual Target

218

Current Accrual

Trial Chairperson

Prof Alan Wigg, Flinders Medical Centre, SA, Australia

A/Prof David Pryor, Princess Alexandra Hospital, QLD, Australia

Trial Contact

SOCRATES_HCC@trog.com.au

Clinical Trial Registration

Related Post

29 July, 2026

TROG to run breast cancer trial in Australia after gaining $2.86m grant

LATEST NEWS: 29 July 2026 TROG Cancer Research is

new TROG Scientific Committee Chair Elect and members
21 July, 2026

New TROG Scientific Committee Chair-Elect and members bring diverse experience

LATEST NEWS: 21 July 2026 The TROG Scientific Committee